Foresite Capital is a venture capital company, which has a specialty in healthcare. In a recent report by drewaltizer.com, the firm made an announcement regarding the appointment of a new venture partner, Dr. Molly He. Molly served at Illumina as the senior director before joining the venture capital firm. Molly brings to Foresite Capital her 15 years of extensive experience in pharmaceutical and genomic research and development. Molly He graduated from Nankai University with a bachelor’s degree in biochemistry.
Jim Tananbaum, who is the CEO of the Foresite Capital, was profoundly delighted to have Molly He on the board. He noted that Molly He’s leadership record of accomplishment and contribution to scientific research were remarkably motivating. Her able leadership and professionalism would come in handy at a time that Foresite Capital continues its portfolio expansion plan of transformational firms. Dr. Molly He is thus an invaluable resource to the venture capital firm. Molly He possesses more than 15 years of relevant experience in the pharmaceutical industry where she spent a large section of her time developing and designing antibodies, which target cancer and immune diseases.
Tananbaum is the founder, chief executive officer and managing director of Foresite Capital. Jim has been working with the company for the past seven years, since 2010. Notably, Jim Tananbaum features a profound experience of more than 25 years in the venture capital sector. With this extensive experience, Jim Tananbaum utilizes it and links it to facilitate the growth and success of his venture capital firm. Before incepting Foresite Capital, Jim Tananbaum worked with Sierra Ventures as well as the renowned Prospect Partners Ventures.
Jim Tananbaum is among the alumni of both Harvard Business School and Yale University. At Yale University, Jim graduated with a bachelor’s degree in economics. At the Harvard Business School, Jim Tananbaum earned his master’s degree in business administration. He additionally attained an MD from the reputed Harvard Medical School. The MD has enabled him in specializing his venture capital company in healthcare matters. Aside from Foresite Capital, Jim Tananbaum holds other worthy investments, including Amira Pharmaceuticals, the Amerigroup, Jazz Pharmaceuticals, and Healtheon. A majority of Jim Tananbaum’s ventures are based at the San Francisco’s Bay Area with Intarcia Therapeutics being among Jim’s prominent deals.
Jim Tananbaum is very competent in his work and has been named to the Forbes list that recognizes the 100 top notch investors. Tananbaum has appeared in this list three consecutive times. According to INC42, this year, he was position 52.